Friday, 5 Sep 2025
  • About Us
  • Contact Us
  • Terms and Conditions
  • Privacy Policy
Subscribe
Life Care News
  • Home
  • Business
    • Business Wire
    • Globenews Wire
  • News
    NewsShow More
    ADFW 2025: World’s Financial Elite Managing Over USD 60 Trillion to Explore How Technology is Shaping Finance
    ADFW 2025: World’s Financial Elite Managing Over USD 60 Trillion to Explore How Technology is Shaping Finance
    05/09/2025
    Starburst Announces AI & Datanova 2025, the Global Virtual Summit for Trino, Data and AI Innovation
    Starburst Announces AI & Datanova 2025, the Global Virtual Summit for Trino, Data and AI Innovation
    05/09/2025
    James Hardie Releases Annual Sustainability Report
    James Hardie Releases Annual Sustainability Report
    04/09/2025
    StudyIn Announces Completion of its Transaction with SUN Education
    StudyIn Announces Completion of its Transaction with SUN Education
    04/09/2025
    ERA Congress: Long-term data show sustained efficacy and safety of zigakibart in patients with IgA nephropathy
    Coventry and Alan Buerger Move to Dismiss Abacus Lawsuit
    03/09/2025
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
  • 🔥
  • news
  • june
  • global
  • Business
  • july
  • today
  • announced
  • aug
  • company
  • Tech
Font ResizerAa
Life Care NewsLife Care News
  • Home
  • Business
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Search
  • Home
  • Business
    • Business Wire
    • Globenews Wire
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Follow US
© 2022 Foxiz News Network. Ruby Design Company. All Rights Reserved.
Health

ERA Congress: Long-term data show sustained efficacy and safety of zigakibart in patients with IgA nephropathy

PRNW Agency
Last updated: 05/06/2025 7:53 AM
PRNW Agency
Share
2 Min Read
ERA Congress: Long-term data show sustained efficacy and safety of zigakibart in patients with IgA nephropathy
SHARE
ERA Congress: Long-term data show sustained efficacy and safety of zigakibart in patients with IgA nephropathy

VIENNA, June 5, 2025 /PRNewswire/ — New 100-week data from the ongoing Phase 1/2 study of zigakibart, an investigational anti-APRIL monoclonal antibody, reinforce its potential as a disease-modifying treatment for IgA nephropathy (IgAN). Findings presented today at the 62nd ERA Congress demonstrate sustained proteinuria remission, stable kidney function, and a reassuring safety profile.

- Advertisement -

IgAN is the most common form of glomerular disease worldwide and a frequent cause of chronic kidney disease. Its pathogenesis is marked by inflammation and progressive kidney damage, which can lead to kidney failure. Many patients are unaware they have the condition until significant kidney damage has occurred, and 50% of IgAN patients will ultimately develop kidney failure.

- Advertisement -

By targeting the APRIL pathway and reducing production of pathogenic galactose-debecause ofgA1), zigakibart addresses a key driver of disease progression. “Zigakibart is designed to intercept the initiating factor in IgAN pathogenesis, offering a new approach that may halt or significantly delay progression”, explained lead investigator Professor Jonathan Barratt.

The ADU-CL-19 trial included 40 adults with biopsy-confirmed IgAN and persistent proteinuria despite stable supportive therapy. Patients received zigakibart every two weeks via intravenous infusion or subcutaneous injection, in addition to maximally tolerated renin–angiotensin system inhibitors (RASi) unless RASi-intolerant – demonstrating efficacy beyond standard care.

- Advertisement -

At Week 100, proteinuria was reduced by 60% from baseline. Over half of patients (55%) reached <500 mg/24 h, and 31% achieved <300 mg/24 h, indicating deeper remission. Estimated glomerular filtration rate (eGFR) remained stable across subgroups. "The consistency of eGFR stabilisation over 100 weeks, even across proteinuria response groups, is particularly encouraging," said Prof. Barratt.

- Advertisement -

Treatment also led to sustained reductions in serum immunoglobulins, including a 74% drop in IgA and pathogenic Gd-IgA1, consistent with APRIL pathway inhibition.

Zigakibart was well tolerated throughout. Most adverse events were mild or moderate, with no treatment-related serious infections or discontinuations. Infections were the most common AEs; the study coincided with a high prevalence of COVID-19.

- Advertisement -

This is the longest duration of eGFR stabilisation reported for an anti-APRIL agent in IgAN. “These long-term results build confidence in zigakibart as a potential cornerstone therapy for IgAN,” said Prof. Barratt. “We’re excited to see how the upcoming Phase 3 trials will further define its role.”

- Advertisement -

The global Phase 3 BEYOND study is now evaluating zigakibart in a broader population, with primary proteinuria endpoints at 40 weeks and long-term kidney function through 104 weeks.

View original content:https://www.prnewswire.co.uk/news-releases/era-congress-long-term-data-show-sustained-efficacy-and-safety-of-zigakibart-in-patients-with-iga-nephropathy-302470916.html

- Advertisement -
Xinhua Silk Road: Summer music feast draws crowds of attendees in “Ice City” in NE. China
Vital Materials Released Quantum Flux Photon Counting CT (PCCT) Full Vertical Integration Technology
IOC President and new Pope meet in person in Rome
The Dermatology Group of Arkansas Welcomes Double Board-Certified Dermatologist to Practice
Manufacturers and Logistics Providers Embrace AI for Enhanced Barcode Reading Performance
TAGGED:antiaprilantibodydamagedatadiseasediseasemodifyingfailurefindingsigaiganinvestigationaljunekidneyleadmonoclonalnephropathyof zigakibartongoingpathogenesispatientsphasepotentialpresentedprogressionreinforcestudytreatmentviennaweekzigakibart
Share This Article
Facebook Copy Link Print
- Advertisement -

Your Trusted Source for Accurate and Timely Updates!

Our commitment to accuracy, impartiality, and delivering breaking news as it happens has earned us the trust of a vast audience. Stay ahead with real-time updates on the latest events, trends.
FacebookLike
XFollow
PinterestPin
InstagramFollow
YoutubeSubscribe
LinkedInFollow
MediumFollow

Most Selling Products

Top Picks, Trending Now – Discover the Best Sellers!
Tecno Camon 20 Premier 5G

Tecno Camon 20 Premier 5G

Dark Welkin | 8GB RAM + 512GB Storage (Expandable RAM up to 16GB) | Industry’s 1st 50MP RGBW-Pro Camera | Segment-First 108MP Ultra-Wide Macro Lens | 6.67" 120Hz 10-bit AMOLED In-Display

iQOO Z10 Lite 5G

iQOO Z10 Lite 5G

Titanium Blue | 6GB RAM + 128GB Storage | Dimensity 6300 5G with 433K+ AnTuTu Score | Robust 6000mAh Battery | IP64 Rated + Military-Grade Shock Resistance

OnePlus 13s

OnePlus 13s

Black Velvet | 12GB RAM + 256GB Storage | Flagship Snapdragon® 8 Elite Chipset | Exceptional Battery Life in a Compact Form | Lifetime Display Warranty Included

Samsung Galaxy A55 5G

Samsung Galaxy A55 5G

Awesome Iceblue | 8GB RAM + 256GB Storage | Premium Metal Frame | 50MP OIS Main Camera with Nightography | IP67 Water & Dust Resistance | Gorilla Glass Victus+ | sAMOLED Display with Vision Booster

You Might Also Like

Algorand Foundation and Paycode Announce Partnership to Expand Financial Inclusion on Blockchain
Business

Algorand Foundation and Paycode Announce Partnership to Expand Financial Inclusion on Blockchain

23/06/2025
ERA Congress: Long-term data show sustained efficacy and safety of zigakibart in patients with IgA nephropathy
Health

Frost & Sullivan Names Dassault Systmes as Recipient of Its 2025 Global Transformational Innovation Leadership Award for Excellence in Smart Manufacturing Life Sciences Solutions

19/06/2025
ZEISS showcases expansion of ophthalmic care options creating industry-leading workflow solutions; marks new refractive and cataract milestones
Health

ZEISS showcases expansion of ophthalmic care options creating industry-leading workflow solutions; marks new refractive and cataract milestones

03/09/2025
Muscle Gain & Strength Supplements: How CrazyBulk Muscle Building Supplements Boost Strength and Maximize Muscle Performance Fast
Health

Muscle Gain & Strength Supplements: How CrazyBulk Muscle Building Supplements Boost Strength and Maximize Muscle Performance Fast

18/07/2025
Life Care News
Facebook Twitter Youtube Rss Medium

Life Care News:


We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.

Top Categories
  • Home
  • Business
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Usefull Links
  • About Us
  • Contact Us
  • Terms and Conditions
  • Privacy Policy
Copyright © 2015 – 2025 LifeCareNews Network. All Rights Reserved. LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Life Care NewsLife Care News
Copyright © 2015 - 2025 LifeCareNews Network. All Rights Reserved. LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?